Alzamend Neuro’s AL001 Brain-Imaging Research Takes the Stage at ISMRM

Key Points

• AL001 data will be presented during a 10-minute oral session on September 29, 2026, at the ISMRM X-Nuclei MR Workshop.
• The completed Phase 1/2A study used 7-Tesla MRI and magnetic resonance spectroscopy to measure lithium in the blood, whole brain, and specific brain regions.
• Alzamend previously reported that AL001 achieved blood lithium exposure comparable with standard lithium carbonate and showed numerically higher lithium levels across all 26 measured brain regions.
• AL001 is not approved for any use, and the findings do not show that it improves symptoms, reduces toxicity, or provides better patient outcomes.

Alzamend Neuro, Inc. (Nasdaq: ALZN) will present Phase 1/2A data for AL001, its investigational lithium formulation, at an International Society for Magnetic Resonance in Medicine, or ISMRM, workshop in Barcelona. The presentation will examine how AL001 distributes lithium in the brain compared with standard lithium carbonate.

 7T Imaging Study Compares AL001 With Standard Lithium

The completed study enrolled healthy participants in a randomized crossover trial. Participants received AL001 and lithium carbonate in separate 14-day dosing periods, with a 14-day washout between treatments. Researchers then collected 24-hour blood samples and used advanced imaging to assess lithium concentrations throughout the brain.

Alzamend said AL001 produced 101% of the total blood lithium exposure and 97% of peak lithium levels compared with standard lithium carbonate. The company also reported that AL001 showed numerically higher lithium levels in all 26 measured brain regions, including a reported 7.8% increase in maximum whole-brain lithium exposure.

Scientific Presentation Supports Ongoing AL001 Development

The Barcelona presentation gives Alzamend an opportunity to share its imaging results with magnetic-resonance researchers. However, the abstract’s acceptance is not an FDA decision, peer-reviewed publication, or clinical endorsement of AL001.

AL001 is designed as an organic lithium formulation that may improve lithium delivery to the brain. Traditional lithium therapy can require close blood-level monitoring because of its narrow therapeutic range and possible systemic side effects. Alzamend has not yet shown that AL001 reduces those risks.

Bipolar Disorder Trial Is the Next Clinical Test

Alzamend is also conducting a Phase 2 study of AL001 in people with bipolar I disorder at Massachusetts General Hospital. The trial compares AL001 with lithium carbonate and is designed to assess lithium levels in blood and brain tissue, safety, and brain-metabolism measures. The study is estimated to complete in December 2026.

For ALZN investors, the key milestones are detailed findings from the September ISMRM presentation, Phase 2 patient data, safety updates, clinical-development plans, and the company’s funding needs. The long-term value of AL001 will depend on whether it can demonstrate meaningful benefits in patients.